These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36429040)

  • 1. Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment.
    Koch M; Nickel S; Lieshout R; Lissek SM; Leskova M; van der Laan LJW; Verstegen MMA; Christ B; Pampaloni F
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for inducing branching morphogenesis in human cholangiocyte and cholangiocarcinoma organoids.
    Ober K; Roos FJM; van Tienderen GS; Köten K; Klaassen A; Mi W; van der Laan LJW; Verstegen MMA
    STAR Protoc; 2023 Sep; 4(3):102431. PubMed ID: 37432852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Derived Organoids of Cholangiocarcinoma.
    Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
    J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.
    Lozano E; Macias RIR; Monte MJ; Asensio M; Del Carmen S; Sanchez-Vicente L; Alonso-Peña M; Al-Abdulla R; Munoz-Garrido P; Satriano L; O'Rourke CJ; Banales JM; Avila MA; Martinez-Chantar ML; Andersen JB; Briz O; Marin JJG
    Hepatology; 2019 Oct; 70(4):1246-1261. PubMed ID: 30972782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental value of volumetric multiparametric MRI over Fudan score for prognosis of unresectable intrahepatic cholangiocarcinoma treated with systemic chemotherapy.
    Pandey A; Mohseni A; Shaghaghi M; Pandey P; Rezvani Habibabadi R; Hazhirkarzar B; Ly A; Panid Madani S; Borhani A; Kamel IR
    Eur J Radiol; 2024 Jan; 170():111196. PubMed ID: 38029705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Aminolevulinic acid-mediated photodynamic activity in patient-derived cholangiocarcinoma organoids.
    Fujiwara H; Takahara N; Tateishi K; Tanaka M; Kanai S; Kato H; Nakatsuka T; Yamamoto K; Kogure H; Arita J; Nakai Y; Kasuga M; Ushiku T; Hasegawa K; Koike K
    Surg Oncol; 2020 Dec; 35():484-490. PubMed ID: 33126085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
    Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
    Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
    LaRocca RV; Hicks MD; Mull L; Foreman B
    J Gastrointest Cancer; 2007; 38(2-4):154-6. PubMed ID: 19089671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes.
    Song Z; Lin S; Wu X; Ren X; Wu Y; Wen H; Qian B; Lin H; Huang Y; Zhao C; Wang N; Huang Y; Peng B; Li X; Peng H; Shen S
    Hepatol Int; 2023 Oct; 17(5):1300-1317. PubMed ID: 37368186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
    Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
    Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
    Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
    Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
    Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Establishment and application of intrahepatic cholangiocarcinoma organoid models].
    Liu Y; Liang X
    Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):346-352. PubMed ID: 38432677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remarkable tumor shrinkage in hilar biliary cholangiocarcinoma confirmed by peroral cholangioscopy following neoadjuvant chemotherapy.
    Tomishima K; Suzuki A; Ito K; Ishii S; Fujisawa T; Fukumura Y; Isayama H
    Endoscopy; 2024 Dec; 56(S 01):E85-E86. PubMed ID: 38290706
    [No Abstract]   [Full Text] [Related]  

  • 17. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass-forming intrahepatic cholangiocarcinoma presenting tumor growth in extrahepatic bile duct and superficial spreading.
    Regimbeau JM; Panis Y; Nemeth J; Pocard M; de Claviere G; Soyer P; Valleur P
    Hepatogastroenterology; 2003; 50(49):21-3. PubMed ID: 12629982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
    Qun W; Tao Y
    Hepatogastroenterology; 2010; 57(99-100):426-9. PubMed ID: 20698202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells.
    Zhou G; Lieshout R; van Tienderen GS; de Ruiter V; van Royen ME; Boor PPC; Magré L; Desai J; Köten K; Kan YY; Ge Z; Campos Carrascosa L; Geuijen C; Sprengers D; van der Laan LJW; Verstegen MMA; Kwekkeboom J
    Br J Cancer; 2022 Sep; 127(4):649-660. PubMed ID: 35597867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.